2-Year Follow-Up: PRISM Phase 2b Clinical Trial Evaluating Investigational 4D-150, an Intravitreal Gene Therapy, in a Broad Neovascular AMD Population

First-time data release

Carl C. Awh, MD, FASRS
Tennessee Retina
Nashville, TN

On behalf of the PRISM study investigators

Disclosures

Consultant:	Bausch + Lomb, Genentech, Inc., Ocular Therapeutix, Zeiss
Royalties:	Bausch + Lomb, Harrow, Katalyst Surgical/Zeiss
Speakers Bureau:	Genentech, Inc.
Investigator:	4D Molecular Therapeutics, Adverum, Allergan, Apellis, Astellas/AIRM, Aura, Aviceda, Chengdu, Kanghong, Cognition, Eluminex, Genentech, Inc., Ionis, Kodiak Sciences, Mylan, NGM Bio, Ocular Therapeutix, Oxurion, Regeneron, Regenxbio, Stealth

4D-150: A Novel, R100-Based Dual-Transgene Investigational Gene Therapy

Delivery Vehicle: AAV Capsid (R100)



R100 AAV Capsid Specifically Designed via Therapeutic Vector Evolution for:

- Administration by routine intravitreal injection
- Crossing of vitreoretinal barriers
- Selective and efficient transduction of retinal cells

Dual Transgene Payload: 4D-150



AAV, adeno-associated virus; PIGF, placental growth factor; RNAi, RNA interference; VEGF, vascular endothelial growth factor.

PRISM Clinical Trial: Focus on Phase 2b Cohort

Evaluation of 4D-150 in a Broad Range of nAMD Populations

	Phase 1/2a	Phase 2b
Phase 3 Dose 3E10 vg/eye (N)	24	**30**
Population	*Severe, Recalcitrant*	***Broad***
Mean Injections in Last 12 Months	10.2	**4.4**
Mean CST	425 µm	**336 µm**
Mean Time Since Diagnosis	3.7 years	**1.8 years**

CST, central subfield thickness; nAMD, neovascular age-related macular degeneration; vg/eye, vector genomes per eye.

A Single Intravitreal Dose of 4D-150 is Associated with Stable Anatomy and Visual Acuity Through 2 Years in a Broad nAMD Population



Data cutoff of May 18, 2026.
Aflibercept 2mg dosed at Day -7 and Day 28. 4D-150 dosed at Day 0.
nAMD, neovascular age-related macular degeneration; BCVA, best corrected visual acuity; CST, central subfield thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; vg/eye, vector genomes per eye.

A Single Dose of 4D-150 is Associated with Treatment Burden Reduction in a Broad nAMD Population over 2 Years

>50% of Participants Required 0-1 Supplemental Injection





Data cutoff of May 18, 2026.
*Projection based on approved dosing schedule for aflibercept in wet AMD after loading doses.
AFLB, aflibercept; nAMD, neovascular age-related macular degeneration; vg/eye, vector genomes per eye.

PRISM Clinical Trial: Focus on Phase 2b Cohort

Evaluation of 4D-150 in a Broad Range of nAMD Populations

	Phase 1/2a	Phase 2b	Phase 2b Subgroup
Phase 3 Dose 3E10 vg/eye (N)	24	30	**15**
Population	*Severe, Recalcitrant*	*Broad*	***Recently Diagnosed***
Mean Injections in Last 12 Months	10.2	4.4	**2.7**
Mean CST	425 µm	336 µm	**304 µm**
Mean Time Since Diagnosis	3.7 years	1.8 years	**2.4 months**

*≤0.5 years with previous treatment.
CST, central subfield thickness; nAMD, neovascular age-related macular degeneration; vg/eye, vector genomes per eye.

A Single Intravitreal Dose of 4D-150 is Associated with Stable Anatomy and Visual Acuity Through 2 Years in a Recently Diagnosed* nAMD Population



Data cutoff of May 18, 2026.

*Disease duration ≤6 months. Aflibercept 2mg dosed at Day -7 and Day 28. 4D-150 dosed at Day 0.

nAMD, neovascular age-related macular degeneration; BCVA, best corrected visual acuity; BL, baseline; CST, central subfield thickness; ETDRS, Early Treatment Diabetic Retinopathy Study.

A Single Dose of 4D-150 is Associated with Treatment Burden Reduction in a Recently Diagnosed* nAMD Population over 2 Years

66% of Participants were Supplemental Injection-Free





Data cutoff of May 18, 2026.

*Disease duration ≤6 months. †Projection based on approved dosing schedule for aflibercept in wet AMD after loading doses.

AFLB, aflibercept; nAMD, neovascular age-related macular degeneration; vg/eye, vector genomes per eye.

PRISM Phase 1/2 Follow-up Suggests a Consistent and Predictable Intraocular Inflammation Profile

Highest SUN/NEI Score† with 4D-150 3E10 vg/eye (N=71)



- No 4D-150–related serious adverse events
- No 4D-150–related hypotony, endophthalmitis, occlusive/non-occlusive retinal vasculitis, or choroidal effusions

Data cutoff of May 18, 2026.
†4D-150–related. ‡1+ VC cell in 1 patient at Week 4 & 1 patient Week 28.
NEI, National Eye Institute; SUN, Standardization of Uveitis Nomenclature.

Conclusions: PRISM Clinical Trial Long-Term Results

4D-150 Demonstrated Consistent, Durable, and Predictable Clinical Activity and was Well Tolerated

2-Year Efficacy Data: Phase 2b

- Visual acuity & anatomic control maintained
- Clear and consistent dose-response, consistent with all 4D-150 trials to date
- Consistent treatment burden reduction through 2 years†:

	Treatment Burden Reduction†	Injection Free
Phase 2b Broad	**78%**	**46%**
Phase 2b Recently Diagnosed*	**87%**	**66%**

Safety Data: Phase 1/2a & 2b

- No 4D-150-related SAEs
- No IOI from 28 weeks through 4+ years (SUN/NEI Score)
  - 2.8%‡ IOI observed within 28 weeks
  - 0% IOI after 28 weeks

Data cutoff of May 18, 2026.
*Disease duration ≤6 months. †Projection based on approved dosing schedule for aflibercept in wet AMD after loading doses. ‡1+ vitreous cell in 1 patient at Week 4 & 1 patient Week 28.
SAE, serious adverse event; IOI, intraocular inflammation; SUN, Standardization of Uveitis Nomenclature; NEI, National Eye Institute.

Thank you to all trial investigators, research staff, patients, and caregivers who contributed to this work!